Stocks
Invest in Stocks
Invest in stocks, ETFs, IPOs with fast orders. Track returns on your stock holdings and view real-time P&L on your positions.
F&O
Mutual Funds
Invest in Mutual Funds
Invest in direct mutual funds at zero charges via lump sump investments or SIPs
AKUMS •NSE
Akums Drugs & Pharmaceuticals
₹520.05-1.30 (0.25%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events
Performance
Today’s low
516.60
Today’s high
525.45
52 week low
409.30
52 week high
622.95
Open price
523.50
Previous close
521.35
Live volume
2,21,535
Lower circuit
468.05
Upper circuit
572.05
Fundamentals
Market Cap
₹8,190Cr
ROE
7.70%
P/E Ratio(TTM)
31.94
EPS(TTM)
16.29
P/B Ratio
2.47
Dividend Yield
0.56%
Industry P/E
34.62
Book Value
210.57
Debt to Equity
0.05
Face Value
2
Financial performance
MAR '26
Revenue (Cr)
₹1,193
-0.06%
Profit (Cr)
₹81.34
+20.20%
03006009001.2k
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
| Revenue growth | Value |
|---|---|
| 1Y (TTM) | +11% |
| 3Y CAGR | +4% |
| Profit growth | Value |
|---|---|
| 1Y (TTM) | -46% |
| 3Y CAGR | +50% |
About
Akums Drugs & Pharmaceuticals Limited is a contract manufacturing pharmaceutical company producing formulations for various therapies.;
CEO/MD
Sanjeev Jain, Sandeep Jain
Founded in
2004
NSE symbol
AKUMS
Shareholding Pattern
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Mutual Funds Invested (4)
Similar stocks
| Stock | Mkt price (1D) | 52 week performance | Market cap | P/E ratio | P/B ratio | |
|---|---|---|---|---|---|---|
Syngene InternationalSYNGENE | ₹461.85 -8.35 (1.78%) | 18,605.73 | 58.75 | 3.84 | ||
Cohance LifesciencesCOHANCE | ₹418.55 -1.35 (0.32%) | 16,010.43 | 106.76 | 4.09 | ||
Blue Jet HealthcareBLUEJET | ₹441.05 +1.10 (0.25%) | 7,642.02 | 26.04 | 6.09 | ||
Divi's LaboratoriesDIVISLAB | ₹6,887.00 +29.00 (0.42%) | 1,82,775.12 | 73.73 | 11.86 |
Livesquawk •
Akums Drugs projects a 32% effective tax rate for FY27, aiming at 29% long-term.
The company targets a 25% normal tax rate as businesses turn PAT positive.
Livesquawk •
Akums Drugs plans FY27 CapEx of INR 300 cr for oral solid facilities expansion.
The company is also exploring inorganic opportunities in niche business segments.
Livesquawk •
Akums Drugs expects Trade Generics to maintain stable revenue and EBITDA levels.
The business is not expected to significantly impact the group's top line or profitability.
Livesquawk •
Akums Drugs aims to reduce API segment losses significantly this fiscal.
The firm targets achieving monthly EBITDA positive performance despite yearly losses.
Livesquawk •
Akums Drugs targets double-digit growth in domestic branded formulations, aligning with IPM rates.
Growth supported by new launches, brand building, and enhanced field force productivity.
Livesquawk •
Akums Drugs expects Zambia partnership to begin $25M commercial supplies by Q2 FY27.
The two-year contract will contribute $25M annually in FY27 & FY28 to CDMO revenues.
2026
14
May
Quarterly & Annual Result
Release date
13
Feb
Quarterly Result
Release date
2025
13
Nov
Quarterly Result
Release date
8
Aug
Quarterly Result
Release date
Events calendar
View upcoming events in other stocks